Kashyap Tele-Medicines Ltd

Financial results approved

• Un-Audited Q1 FY2026 results for quarter ended 30 June 2026 approved with Limited Review.
• Revenue from operations Rs 20.00 lakh; total income Rs 20.16 lakh.
• Profit after tax Rs 14.46 lakh; basic/diluted EPS Rs 0.030.
• Quarter ended 30 June 2026; Limited Review by statutory auditors.

Corporate actions and segment info

• Company name changed to June Industries Limited from Kashyap Tele-Medicines Limited, effective 30 Dec 2025.
• Single reportable segment: trading of pharmaceuticals, hygiene and cleanroom products.

Other disclosures

• Board reviewed other business; no additional disclosures provided.

AGM Details

• AGM conducted via VC/OAVM in August 2026, starting around 11:30 a.m.
• Record date set in early August 2026.
• Total shareholders and attendance details reported.
• Meeting concluded around 11:51 a.m. IST.

Resolutions & Voting

• Resolution 1: Ordinary; adoption of audited financial statements and reports.
• Resolution 2: Ordinary; re-appointment of Whole-Time Director (retires by rotation).
• Voting outcome: resolutions passed with majority; minimal opposition.
• Ballot voting used due to temporary e-voting issue; remote results consolidated.
• Scrutinizer confirms resolutions were passed.

AGM Details

• 32nd AGM held Aug 10, 2026 at 11:30 a.m. IST via VC/OAVM; concluded 11:51 a.m.

Resolutions

• Ordinary Resolution: Adoption of audited financial statements for FY ended 31 March 2026 and related reports.
• Ordinary Resolution: Re-appointment of Heena Kalpesh Sheth as Whole-Time Director; retires by rotation.
• Voting results to be announced within 48 hours; will be displayed on company/NSDL websites.

Director Changes

• Re-appointment of Heena Kalpesh Sheth as Whole-Time Director.

AGM & Notice

• 32nd AGM on 10 August 2026 via VC/OAVM.
• Audited financials for FY2025-26 to be adopted.
• NSDL e-voting facility; proxies not allowed for VC/OAVM.
• Annual Report 2025-26 circulated; available on company website.

Financial Performance FY2025-26

• Revenue from operations ₹19.70 L; total income ₹21.58 L.
• Total expenses ₹67.64 L; EBITDA and net loss ₹46.06 L.
• EPS (basic/diluted) near zero; no dividend declared.

Capital Structure & Corporate Actions

• Authorized capital ₹15 Cr; issued ₹5 Cr; paid-up ₹4.7722 Cr.
• No borrowings; balance sheet asset-light.
• Name changed to June Industries Limited; previously Kashyap Tele-Medicines Limited.
• Pivot to pharmaceutical trading; expand pharma, hygiene, cleanroom products.
• June Enterprises Private Limited acquired 60.88% stake; June Industries became subsidiary.
• Open offer; promoter holding after open offer at 60.88%.
• No differential voting rights or stock options issued.

Business Transformation & Name Change

• Shift from IT services to pharmaceutical trading.
• Plan to diversify into formulations, hygiene products, and cleanroom consumables.
• Asset-light model; focuses on sourcing and distribution.
• Management aims for sustainable growth via regulatory compliance and customer focus.

Governance & Board Changes

• Board as of 31 March 2026: 2 Exec, 1 Non-Exec Non-Independent, 3 Independent.
• MD Kalpesh B. Sheth appointed 23 May 2025 for five years.
• Heena K. Sheth appointed Whole-Time Director from 23 May 2025.
• CFO Anirudh Shah appointed 21 July 2025; Raghav Agrawal resigned 24 May 2025.
• Company Secretary Jyoti Sahu resigned 5 Apr 2025; Varsha Sawant appointed 21 Jul 2025.
• Directors added: Samir Ambavi, Hardik Bauva, Hiren Mehta, Mandar Jain in 2025.
• Resignations during year: Amit Agrawal (MD), Ayushman Khemka, Raghav Agrawal (CFO).
• Audit, Stakeholders Relationship, Nomination & Remuneration Committees in place.

Risk Management & Internal Controls

• Risk management policy in place; board/audit committee review.
• Internal controls adequate; no material fraud reported.
• Vigil mechanism/Whistle Blower policy established.
• Secretarial audit: no qualifications; compliance with applicable laws.

Regulatory & Compliance Highlights

• Secretarial audit reports: no adverse remarks; AOC-2 not applicable.
• BSE fines in 2024 and 2025; waivers/payments completed.
• Annual Return (MGT-7) available on website.
• Corporate Governance not applicable due to small paid-up capital.

Outlook & Opportunities

• Indian pharmaceutical market remains positive long term; favorable demographics and policy focus.
• Plan to expand product portfolio; leverage digital procurement and inventory tools.
• Risks include regulatory changes, pricing pressures, supply chain disruptions, and working capital.

AGM Details

• 32nd AGM scheduled for 10 August 2026 at 11:30 AM IST via VC/OAVM.
• Register of Members and share transfer books closed from 04 to 10 August 2026.
• Remote e-voting window: 07–09 August 2026; cut-off date: 03 August 2026.
• AGM conducted through VC/OAVM; physical attendance not required.

Key Resolutions

• Ordinary: Adoption of Audited Financial Statements for FY 2025-26.
• Ordinary: Re-appointment of Heena Kalpesh Sheth as Executive Director.

Dividend

• Dividend for FY2025-26 not recommended.

Director Changes & Corporate Actions

• Amit Agrawal resigned as Managing Director on 24 May 2025.
• Kalpesh Bipin Sheth appointed Managing Director from 23 May 2025.
• Heena Kalpesh Sheth appointed Whole-Time Director from 23 May 2025.
• Samir Ambavi appointed Additional Non-Executive Director on 23 May 2025; regularised 24 Sep 2025.
• Raghav Agrawal resigned as Director and CFO on 24 May 2025.
• Ayushman Khemka resigned as Director on 24 May 2025.
• Hardik Bauva appointed Additional Independent Director from 21 July 2025.
• Hiren Mehta appointed Additional Independent Director from 21 July 2025.
• Mandar Jain appointed Additional Independent Director from 21 July 2025.
• Jyoti Sahu resigned as Company Secretary on 05 Apr 2025; Varsha Sawant appointed 21 Jul 2025.
• June Enterprises Private Limited acquired 60.88% stake; becomes holding company.
• Company changed name from Kashyap Tele-Medicines Limited to June Industries Limited.
• Business changed to pharmaceutical trading; approved via postal ballot Aug 2025.

Auditors

• Statutory Auditors Shah Valera & Associates LLP appointed for five years to 2030-31.
• Secretarial Auditor Rupal Patel appointed for five years from 2025-26.
• Internal Auditor Bhavesh D Shah & Co appointed for FY2025-26.

Material Related Party Transactions

• No related party transactions during the year.

Other Material Approvals

• Name change approved; company renamed to June Industries Limited.
• Change in nature of business to pharmaceutical trading approved; Aug 2025.
• Acquisition by June Enterprises Private Limited; holding company status achieved.

Dematerialisation status

• Dematerialisation requests processed; securities confirmed to the depositories during the period.
• Securities dematerialised were listed on the stock exchanges where the prior securities are listed.
• Physical certificates received for dematerialisation were mutilated and cancelled; depository name substituted as registered owner within timelines.
• No exceptions, delays, or non-compliance reported.

Governance approvals

• Approved Director's Report for year ended 31 March 2026.
• Adopted Secretarial Audit Report under Section 204(1) for year ended 31 March 2026.

Shareholder meeting

• Approved 32nd AGM on 10 August 2026 at 11:30 IST via video conferencing.
• Draft AGM Notice approved.

Share registry and notices

• Register of Members and Share Transfer Books close 04-10 August 2026.

Appointed Scrutinizer

• Appointed Mrs. Rupal Patel, PCS, as Scrutinizer for remote e-voting and AGM.

Other business

• Reviewed other business of the company.

Meeting Details

• Date: 04 July 2026; Time: not disclosed; Venue: Registered Office.

Key Agenda Items

• To consider and approve Director's Report and Secretarial Audit Report for year ended 31 March 2026.
• To fix day, date, time and venue for the Annual General Meeting.
• To decide dates for closure of the Members Register and Share Transfer Register.
• To consider and approve draft notice for the Annual General Meeting.
• To appoint Scrutinizer for remote e-voting and AGM voting.

Other Notes

• Trading window closure periods are not specified in the filing.